Загрузка страницы

How Are Connective Tissue Diseases and Pulmonary Arterial Hypertension Related?

This video is part of a larger CE/CME Certified program entitled: A Most Difficult Patient – Treating Connective Tissue Disease Related PAH. You can receive free CME credit, view this video, and download slides from the presentation at MedEdOnTheGo.com.

Видео How Are Connective Tissue Diseases and Pulmonary Arterial Hypertension Related? канала MedEdOTG
Показать
Комментарии отсутствуют
Введите заголовок:

Введите адрес ссылки:

Введите адрес видео с YouTube:

Зарегистрируйтесь или войдите с
Информация о видео
12 декабря 2019 г. 0:22:38
00:06:32
Другие видео канала
How the Presence of PoPH, With or Without Treatment, Impacts Patients Who Need A Liver TransplantHow the Presence of PoPH, With or Without Treatment, Impacts Patients Who Need A Liver TransplantShould I Use Checkpoint Inhibitors in Advanced NSCLC with Targetable Molecular Alterations?Should I Use Checkpoint Inhibitors in Advanced NSCLC with Targetable Molecular Alterations?Emerging Agents and Combinations to Treat RET Fusion-Positive Lung CancersEmerging Agents and Combinations to Treat RET Fusion-Positive Lung CancersPanel Discussion:  Challenges and Opportunities to Managing EGFR Exon 20 MutationsPanel Discussion: Challenges and Opportunities to Managing EGFR Exon 20 MutationsOptimizing ED Triage Strategies for Agitated BD & SCZ PatientsOptimizing ED Triage Strategies for Agitated BD & SCZ PatientsImproving Patient Outcomes: Beneficial & Adverse Effect Profiles of SCZ Antipsychotic AgentsImproving Patient Outcomes: Beneficial & Adverse Effect Profiles of SCZ Antipsychotic AgentsAML Risk Stratification: Cytogenetics and Mutational Analysis - Part 1AML Risk Stratification: Cytogenetics and Mutational Analysis - Part 1Thinking Out of the Box: Monotherapies versus Adjunctive Therapies in Bipolar I and II DepressionThinking Out of the Box: Monotherapies versus Adjunctive Therapies in Bipolar I and II DepressionSingle or Dual Agent IO/Chemotherapy for PD-L1 Negative NSCLCSingle or Dual Agent IO/Chemotherapy for PD-L1 Negative NSCLCCase: Aunt Judy Has Been Hallucinating - Treatment Interventions for Parkinson’s Disease PsychosisCase: Aunt Judy Has Been Hallucinating - Treatment Interventions for Parkinson’s Disease PsychosisYou are not alone!  Patient Advocacy and OrganizationsYou are not alone! Patient Advocacy and OrganizationsPediatric BPDCN and Use of Tagraxofusp in ChildrenPediatric BPDCN and Use of Tagraxofusp in ChildrenJAK Inhibition in SR cGVHD: REACH 3, GRAVITAS-309JAK Inhibition in SR cGVHD: REACH 3, GRAVITAS-309Which Combination Therapy Do I Choose for Frontline Treatment of MPM?Which Combination Therapy Do I Choose for Frontline Treatment of MPM?Bleeds with Vitamin K Antagonist Managed in the ED or ICUBleeds with Vitamin K Antagonist Managed in the ED or ICUSelecting and Managing RET-Targeted Therapy in mNSCLCSelecting and Managing RET-Targeted Therapy in mNSCLCTAAR1: What Is the Role of TAAR1 Agonism for the Treatment of Schizophrenia?TAAR1: What Is the Role of TAAR1 Agonism for the Treatment of Schizophrenia?EGFR TKI Resistance: Targeting MET AmplificationEGFR TKI Resistance: Targeting MET AmplificationHow Easy Is It to Use Risk Assessment Algorithms?How Easy Is It to Use Risk Assessment Algorithms?When Should I Combine Checkpoint Inhibitors in First-Line Advanced NSCLC?When Should I Combine Checkpoint Inhibitors in First-Line Advanced NSCLC?What’s Next After I Use Checkpoint Inhibitor Combination Therapy First-line in Advanced NSCLC?What’s Next After I Use Checkpoint Inhibitor Combination Therapy First-line in Advanced NSCLC?
Яндекс.Метрика